Compare L3Harris Technologies Inc (LHX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Merck & Co., Inc. — how do they compare? L3Harris Technologies Inc trades at $236.8 (market cap $44.12B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8× L3Harris Technologies Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Merck & Co., Inc. for 98 Days on average.
| LHX | MRK | |
|---|---|---|
Market Cap | $44.12B | $351.28B |
Volume | 1,202,852 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $378.48 | $156.43 |
52-Week Low | $233.63 | $82.49 |
Typical Hold Time | 56 Days | 98 Days |
Enterprise Value | $54.56B | $398.04B |
Dividend Yield | 2.11% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.15, up 1.51% on the day, with a bearish technical signal from moving averages but strong fundamental performance, including three consecutive quarterly EPS beats. The company secured major defense contracts totaling over $10.7 billion in September 2026, supporting future revenue growth. Profit margins have improved steadily, with net income margin reaching 7.34% in 2025, and cash flow from operations strengthened to $3.11 billion.
The outlook is positive given robust contract wins and earnings momentum, but risks include ongoing legal investigations and high debt levels. Analyst consensus is strongly bullish with a $340 price target, implying significant upside from current levels, though technical indicators suggest near-term resistance around $238-$240.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
